Scientists reprogrammed two widely used “chemically induced proximity” systems in a recent chemical science paper. CIP systems are very simple: when a small molecule is added, two engineered protein parts are forced to come together or separate out, causing downstream effects like signaling, gene expression or changes in the protein’s location within the cell.
Researchers reprogrammed the CIP platforms by genetically encoding them into nanobodies, producing a rapamycin-controlled dissociation tool and a caffeine-controlled heterodimerization tool, rather than creating a new chemistry from the ground up.
Unlike the previous caffeine-based system, the first tool created is called CHASER, also known as caffeine-induced heterodimerization via anti-mCherry nanobody scaffold engineering and reprogramming.
CHASER showed low baseline interaction in the absence of caffeine and quick activation following caffeine addition.
The researchers demonstrated that caffeine-induced recruitment could drive controlled gene expression with little background activity and activate downstream signaling pathways, such as calcium signaling and mitogen-activated protein kinase and extracellular signal-regulated kinase pathways.
The second tool, RASER, also known as rapamycin-induced dissociation via anti-mCherry nanobody scaffold engineering and reprogramming, represents a conceptual shift. Instead of promoting association, rapamycin binding causes dissociation of the nanobody-target interaction.
This created a chemically triggered off switch. The researchers demonstrated RASER’s potential in a CRISPR activation system. Rapamycin treatment led to dissociation of the transcriptional activator complex, significantly reducing gene expression.
This ability to shut down activity on demand addresses a major limitation of classical rapamycin-based systems, which often lack reversibility.
When combined, CHASER and RASER increase the chemically induced proximity toolkit without the need for completely new chemical substances. These developments demonstrate how synthetic biology continues to improve the accuracy and adaptability of cellular engineering using well-known molecules like caffeine and rapamycin in completely new ways.
Future gene and cell therapies may be safer and easier to regulate. Researchers are working on ways to use safe tiny molecules to turn on and off specific cell functions.
This could allow doctors to reduce or stop a treatment if it starts to cause issues.
This is particularly crucial for therapies like cancer immunotherapy and gene editing, where cells are modified to fight illness but occasionally become overly active. More accurate control over cell behavior may lessen side effects and increase the dependability of treatments.
Even though this research is still in the lab and not yet available to patients, it advances medicine toward more individualized, reversible and adjustable treatments.
By re-engineering nanobody scaffolds, the researchers transformed existing small molecule systems into more versatile biological control mechanisms that enable caffeine and rapamycin to regulate protein interactions.